drugset / Trial / NCT04853901

Remdesivir Efficacy In Management Of COVID-19 Patients

NCT04853901

Phase 3 Completed 77 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is open label randomized interventional phase 3 clinical trial. Patients with confirmed Covid-19 cases who was hospitalized in Two university isolation hospitals (Ain Shams University and Assiut University ) assigned hospitals for isolation.

Timeline

Start
2020-07-27
Primary completion
2021-01-01
Completion
2021-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroxycoloroquine Unknown 200 mg
Subject Remdesivir Small molecule 100 mg Intravenous
Comparator Methylprednisolone Other / unclassified 1 mg/kg
Comparator Methylprednisolone Other / unclassified 2 mg/kg

Indications